Although N6-methyladenosine (m6A) modification has been implicated in the pathogenesis of abdominal aortic aneurysm (AAA), the relationship between m6A-associated single nucleotide polymorphisms (m6A-SNPs) and AAA remains unknown. This study used integrative multi-omics analysis and clinical validation approaches to systematically identify potential m6A-SNPs connected with AAA risk. We found that rs6859 and rs10198139 could modulate the expression of local genes, NECTIN2 and HPCAL1, respectively, which exhibited upregulation in AAA tissues, and their risk variants were significantly correlated with an increased susceptibility to AAA. Incorporating rs6859 and rs10198139 improved the efficiency of AAA risk prediction compared to the model considering only conventional risk factors. Additionally, these two SNPs were predicted to be located within the regulatory sequences, and rs6859 showed a substantial impact on m6A modification levels. Our findings suggest that m6A-SNPs rs6859 and rs10198139 confer an elevated risk of AAA, possibly by promoting local gene expression through an m6A-mediated manner.
26 August 2025 in Ultrasound in Medicine & Biology
Background: Coronary slow flow (CSF) is an angiographic entity characterized by delayed coronary opacification with no evident obstructive lesion in the epicardial coronary artery. Several studies have shown that the occurrence and development of CSF may be closely related to inflammation. Soluble vascular cell adhesion molecule-1 (sVCAM-1) is a biomarker related to inflammation. The aim of this study was to evaluate the correlation between plasma soluble VCAM-1 level and CSF occurrence and thus the predictive value of VCAM-1 for CSF. Methods: Forty-six CSF patients and thirty control subjects were enrolled. Corrected thrombolysis in myocardial infarction frame count (cTFC) was used to diagnose CSF. Functional status and quality of life were determined by the Seattle Angina Questionnaire (SAQ). Echocardiography was used to evaluate the systolic and diastolic function of the left ventricle (LV) and right ventricle (RV). The plasma levels of sVCAM-1, IL-6, and TNF-α were quantified by enzyme-linked immunosorbent assay. Results: Compared with the control group, the physical limitation score by the SAQ, the LV global longitudinal strain (GLS), mitral E, and mitral E/A decreased in patients with CSF, while the plasma IL-6 and TNF-α levels increased. The plasma sVCAM-1 level in the CSF group was significantly higher than that in the control group (186.03 ± 83.21 vs. 82.43 ± 42.12 ng/mL, p < 0.001), positively correlated with mean cTFC (r = 0.57, p < 0.001), and negatively correlated with the physical limitation score (r = −0.32, p = 0.004). Logistic regression analyses confirmed that plasma sVCAM-1 level (OR = 1.07, 95%CI: 1.03–1.11) is an independent predictor of CSF, and the receiver operating characteristic curve analysis showed that plasma sVCAM-1 levels had statistical significance in predicting CSF (area under curve = 0.88, p < 0.001). When the sVCAM-1 level was higher than 111.57 ng/mL, the sensitivity for predicting CSF was 87% and the specificity was 73%. Conclusions: Plasma sVCAM-1 level can be used to predict CSF and was associated with the clinical symptoms of patients. It may serve as a potential biomarker for CSF in the future.
Background: High body mass index (BMI) is a recognized risk factor for cardiovascular diseases, but its impact on aortic aneurysms (AA) remains unclear. This study analyzes the global burden of AA attributed to high BMI in 204 countries between 1990 and 2021. Methods: Using Global Burden of Disease (GBD) 2021 data, we analyzed AA-related deaths, disability-adjusted life years (DALYs), and age-standardized rates (ASRs), assessing 1990–2021 trends via estimated annual percentage change (EAPC) and projecting 2022–2040 burden with Bayesian Age-Period-Cohort (BAPC) model. The BMI-AA association was investigated through multivariable logistic regression and subgroup analyses in UK Biobank (UKB) participants, supplemented by Mendelian randomization (MR) analyses using Integrative Epidemiology Unit Open GWAS Project (IEU OpenGWAS project) summary statistics. Results: In 2021, AA deaths and DALYs due to high BMI rose to 11 540 and 247 361, respectively, compared to 1990. Despite this increase, ASMR and ASDR declined, with EAPCs of −1.36 and −1.13, respectively. The burden of AA due to high BMI increased in individuals under 45 but decreased significantly in those over 65. Males exhibited higher burden than females, though reductions were greater in males. High sociodemographic index (SDI) regions had elevated burden but declining trends. After adjusting for potential confounding factors, individuals with BMI ≥30 kg/m 2 exhibited a higher risk of AA (OR: 1.28, 95% CI: 1.13–1.46, P = 0.001) compared to those with BMI ≤23 kg/m 2 , and subgroup analyses revealed significant interactions for gender and drinking. MR was adopted to estimate the causal relationships between BMI and AA, and demonstrated that genetically predicted higher BMI was associated with an increased risk of AA. By 2040, the global burden of AA attributable to high BMI is projected to gradually rise. Conclusion: Our study highlights that high BMI-related AA remains a major global health issue, with younger men, older women, and lower SDI countries bearing greater burdens. Both UKB data and MR analyses confirm a robust link between elevated BMI and AA risk. Effective BMI management strategies are essential to reduce the future global burden of AA.